Profile data is unavailable for this security.
About the company
Gentian Diagnostics ASA is a Norway-based company within health care sector. The Company develops and manufactures in vitro diagnostic (IVD) products for the detection and quantification of specific markers for use on a wide range of clinical chemistry analysers. The Company’s product portfolio comprises turbidimetric fecal calprotectin immunoassay, which is to be run on clinical chemistry analysers: The Gentian Calprotectin Immunoassay, Cystatin C, NT-proBNP - Pre-launch, SARS-CoV-2 Ab Pre-Launch, Canine CRP and Beckman Coulter Customers. The Company is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China.
- Revenue in NOK (TTM)142.22m
- Net income in NOK-5.83m
- Incorporated2001
- Employees58.00
- LocationGentian Diagnostics ASABjornasveien 5MOSS 1596NorwayNOR
- Websitehttps://www.gentian.com/
More ▼
Mergers & acquisitions
| Acquired company | GENT:OSL since announced | Transaction value |
|---|---|---|
| Getica AB | -17.03% | -- |
Data delayed at least 15 minutes, as of May 16 2024.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lifecare ASA | 13.09m | -35.26m | 417.41m | 32.00 | -- | 6.29 | -- | 31.90 | -0.2903 | -0.2903 | 0.1088 | 0.4924 | 0.1621 | -- | 4.90 | 408,943.10 | -43.60 | -40.00 | -49.97 | -45.26 | -- | -- | -269.03 | -175.53 | -- | -- | 0.1812 | -- | -40.88 | 30.29 | -101.74 | -- | -- | -- |
| INIFY Laboratories AB | 3.41m | -51.33m | 426.49m | 23.00 | -- | 5.84 | -- | 124.90 | -1.13 | -1.13 | 0.0755 | 1.61 | 0.032 | 2.99 | 0.6608 | -- | -48.10 | -- | -48.10 | -- | 76.42 | -- | -1,503.10 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Mendus AB (publ) | 0.00 | -101.51m | 451.72m | 30.00 | -- | 0.5499 | -- | -- | -0.2554 | -0.2554 | 0.00 | 0.8165 | 0.00 | -- | -- | 0.00 | -14.77 | -18.84 | -15.78 | -20.21 | -- | -- | -- | -28,474.53 | -- | -- | 0.0325 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -35.65m | 478.35m | 2.00 | -- | 27.27 | -- | -- | -0.6567 | -0.6567 | 0.00 | 0.3319 | 0.00 | -- | -- | 0.00 | -58.55 | -65.10 | -62.50 | -70.59 | -- | -- | -- | -- | -- | -- | 0.5804 | -- | -- | -- | 40.52 | -- | -- | -- |
| Promimic AB | 37.03m | -9.21m | 480.82m | 17.00 | -- | 6.27 | -- | 12.99 | -0.5283 | -0.5283 | 2.08 | 4.11 | 0.3994 | -5.63 | 3.00 | 2,180,588.00 | -9.93 | -24.89 | -11.67 | -29.25 | 103.90 | 101.23 | -24.88 | -89.47 | 3.98 | -- | 0.00 | -- | 128.63 | -- | 41.95 | -- | -- | -- |
| Bergenbio ASA | 354.00k | -190.40m | 510.48m | 18.00 | -- | 2.75 | -- | 1,442.03 | -0.2647 | -0.2647 | 0.0002 | 0.0474 | 0.0021 | -- | -- | -- | -111.66 | -66.15 | -176.09 | -78.74 | -- | -- | -53,785.59 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
| Hamlet BioPharma AB | 0.00 | -26.56m | 519.42m | 7.00 | -- | 11.49 | -- | -- | -0.207 | -0.207 | 0.00 | 0.3543 | 0.00 | -- | -- | -- | -63.29 | -83.52 | -69.05 | -107.84 | -- | -- | -- | -- | -- | -- | 0.0984 | -- | -- | -- | -18.87 | -- | 78.01 | -- |
| Enzymatica AB (publ) | 47.23m | -53.61m | 554.20m | 18.00 | -- | 6.61 | -- | 11.73 | -0.3247 | -0.3247 | 0.2866 | 0.4841 | 0.3269 | 1.38 | 6.48 | -- | -37.11 | -27.36 | -39.16 | -33.98 | 64.25 | 65.08 | -113.50 | -66.12 | -- | -23.26 | 0.2502 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| Gentian Diagnostics ASA | 142.22m | -5.83m | 586.05m | 58.00 | -- | 3.87 | 163.70 | 4.12 | -0.3783 | -0.3783 | 9.22 | 9.82 | 0.7646 | 1.85 | 6.35 | 2,452,035.00 | -3.14 | -10.76 | -3.58 | -11.86 | 50.84 | 41.46 | -4.10 | -26.99 | 4.14 | -- | 0.0555 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
| Oncopeptides AB | 35.18m | -248.83m | 610.23m | 57.00 | -- | 6.47 | -- | 17.35 | -1.96 | -1.96 | 0.2776 | 0.4474 | 0.1129 | -- | 1.44 | 617,894.80 | -79.88 | -141.28 | -101.04 | -200.49 | 103.06 | -- | -707.30 | -2,689.06 | -- | -- | 0.7065 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
| Cantargia AB | 0.00 | -279.71m | 670.80m | 22.00 | -- | 3.98 | -- | -- | -1.65 | -1.65 | 0.00 | 0.9186 | 0.00 | -- | -- | 0.00 | -80.18 | -55.08 | -100.27 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
| Intellego Technologies AB | 186.28m | 59.54m | 690.97m | 62.00 | 11.26 | 4.57 | 10.96 | 3.71 | 2.33 | 2.33 | 7.35 | 5.74 | 0.8841 | 3.87 | 3.69 | 3,007,968.00 | 28.26 | -- | 44.00 | -- | 68.73 | -- | 31.96 | -- | 2.07 | 5.82 | 0.1684 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
| Alligator Bioscience AB | 55.43m | -248.51m | 691.31m | 55.00 | -- | -- | -- | 12.47 | -0.4848 | -0.4848 | 0.0999 | -0.0772 | 0.5289 | -- | 8.07 | 956,741.40 | -237.13 | -73.26 | -- | -91.33 | -- | -- | -448.35 | -811.68 | -- | -104.20 | -- | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Orexo AB | 618.40m | -73.32m | 710.76m | 113.00 | -- | 11.50 | 122.68 | 1.15 | -2.13 | -2.13 | 17.98 | 1.78 | 0.6959 | 1.08 | 2.53 | 5,337,069.00 | -8.25 | -6.41 | -20.27 | -9.99 | 88.14 | 86.76 | -11.86 | -11.83 | 0.589 | 0.1386 | 0.8948 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
| Nightingale Health Oyj | 42.50m | -210.05m | 730.13m | 81.00 | -- | 1.07 | -- | 17.18 | -0.2979 | -0.2979 | 0.0603 | 1.50 | 0.0344 | 1.60 | 3.87 | 44,560.98 | -17.02 | -14.20 | -18.12 | -15.69 | 75.81 | 83.57 | -494.25 | -408.50 | 14.15 | -- | 0.0378 | -- | 80.80 | 19.05 | -12.38 | -- | -- | -- |
Data as of May 16 2024. Currency figures normalised to Gentian Diagnostics ASA's reporting currency: Norwegian Krone NOK
33.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Vatne Capital ASas of 31 Aug 2023 | 2.33m | 15.11% |
| Storebrand Asset Management ASas of 31 Jan 2024 | 1.47m | 9.51% |
| Norron ABas of 28 Mar 2024 | 444.04k | 2.88% |
| DNB Asset Management ASas of 31 Aug 2023 | 361.29k | 2.34% |
| Schroder Investment Management Ltd.as of 30 Jun 2023 | 325.00k | 2.11% |
| Equinor Asset Management ASAas of 31 Aug 2023 | 227.88k | 1.48% |
More ▼
Data from 31 Aug 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
